Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunorubicin is indicated in combination with cytarabine for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)
- Conditions
- Acute Myelogenous Leukemia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00136448
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Lymphoblastic Leukemia, Acute
- Interventions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 240
- Registration Number
- NCT00131027
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT00130195
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Kanisa Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00129168
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicinDrug: dexamethasoneDrug: doxorubicinDrug: leucovorinDrug: mercaptopurineDrug: methotrexateDrug: mitoxantroneDrug: AsparaginaseDrug: prednisoneDrug: thioguanineDrug: vincristineRadiation: radiation therapyDrug: allopurinolDrug: bactrim
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 79
- Registration Number
- NCT00109837
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Minor and James Medical, PLLC, Seattle, Washington, United States
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT00101153
- Locations
- 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2012-11-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 410
- Registration Number
- NCT00002925
- Locations
- 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cyclophosphamideDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: etoposideDrug: leucovorin calciumDrug: liposomal cytarabineDrug: mercaptopurineDrug: mesnaDrug: methotrexateDrug: therapeutic hydrocortisoneDrug: thiotepaDrug: vincristine sulfateRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 156
- Registration Number
- NCT00002704
- Locations
- 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 637
- Registration Number
- NCT00085709
- Locations
- 🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Munson Medical Center, Traverse City, Michigan, United States
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Secondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Untreated Adult Acute Myeloid Leukemia
- Interventions
- Biological: oblimersen sodiumDrug: cytarabineDrug: daunorubicin hydrochlorideOther: laboratory biomarker analysis
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 500
- Registration Number
- NCT00085124
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.